Genmab announced termination of Phase 3 development for acasunlimab, a bispecific antibody previously co‑developed with BioNTech, after the program failed to meet strategic objectives. The decision follows BioNTech’s earlier exit from the asset and represents a pipeline pruning move by Genmab to redeploy resources. The termination underscores the risk of complex multispecific biologics and the tough go/no‑go calculus for large, costly late‑stage trials.